<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Rituximab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Rituximab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Rituximab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Rituximab</b>, sold under the brand name <b>Rituxan</b> among others, is a medication used to treat certain autoimmune diseases and types of cancer.<span class="mw-ref" id="cite_ref-AHFS2016_3-0"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers.<span class="mw-ref" id="cite_ref-AHFS2016_3-1"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Doj2018_6-0"><a href="#cite_note-Doj2018-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It is given by slow injection into a vein.<span class="mw-ref" id="cite_ref-AHFS2016_3-2"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Rituximab</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Rituximab.png" tppabs="https://ptable.com/wiki/compounds/I/m/Rituximab.png" data-file-width="1020" data-file-height="625" data-file-type="bitmap" height="184" width="300"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Chimeric (mouse/human)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>CD20</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Rituxan, MabThera, Truxima, others<span class="mw-ref" id="cite_ref-generic_1-0"><a href="#cite_note-generic-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>rituximab-abbs, rituximab-pvvr</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/rituximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/rituximab.html'" tppabs="https://www.drugs.com/monograph/rituximab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a607038.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a607038.html'" tppabs="https://medlineplus.gov/druginfo/meds/a607038.html" class="external text external">a607038</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rituximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rituximab'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rituximab" class="external text external">Rituximab</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_2-0"><a href="#cite_note-Drugs.com_pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_2-1"><a href="#cite_note-Drugs.com_pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Intravenous infusion</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Monoclonal antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XC02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XC02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XC02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XC02" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li><small><abbr class="country-name">EU</abbr>:</small><span> </span>Rx-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>100% (IV)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>30 to 400 hours (varies by dose and length of treatment)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Uncertain: may undergo phagocytosis and catabolism in RES</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=174722-31-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=174722-31-7'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=174722-31-7" class="external text external">174722-31-7</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00073  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00073'" tppabs="https://www.drugbank.ca/drugs/DB00073" class="external text external">DB00073</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=4F4X42SYQ6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=4F4X42SYQ6'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=4F4X42SYQ6" class="external text external">4F4X42SYQ6</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D02994  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D02994'" tppabs="https://www.kegg.jp/entry/D02994" class="external text external">D02994</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201576  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201576'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201576" class="external text external">ChEMBL1201576</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID5040910  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID5040910'" tppabs="https://comptox.epa.gov/dashboard/DTXSID5040910" class="external text external">DTXSID5040910</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.224.382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.224.382'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.224.382" class="external text external">100.224.382</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6416</sub><span>H</span><sub>9874</sub><span>N</span><sub>1688</sub><span>O</span><sub>1987</sub><span>S</span><sub>44</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">143<span style="margin-left:.25em;">860</span>.04</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458438457&page2=Rituximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458438457&page2=Rituximab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458438457&page2=Rituximab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>Common side effects, which often occur within two hours of the medication being given, include rash, itchiness, low blood pressure, and shortness of breath.<span class="mw-ref" id="cite_ref-AHFS2016_3-3"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Other severe side effects include reactivation of hepatitis B in those previously infected, progressive multifocal leukoencephalopathy, and toxic epidermal necrolysis.<span class="mw-ref" id="cite_ref-AHFS2016_3-4"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> It is unclear if use during pregnancy is safe for the baby.<span class="mw-ref" id="cite_ref-AHFS2016_3-5"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_2-2"><a href="#cite_note-Drugs.com_pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.<span class="mw-ref" id="cite_ref-Bos2013_8-0"><a href="#cite_note-Bos2013-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> When it binds to this protein it triggers cell death.<span class="mw-ref" id="cite_ref-AHFS2016_3-6"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>
 

<p>Rituximab was approved for medical use in 1997.<span class="mw-ref" id="cite_ref-Bos2013_8-1"><a href="#cite_note-Bos2013-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_9-0"><a href="#cite_note-WHO21st-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span>  The patent expired in 2016, and a number of biosimilars have been launched.<span class="mw-ref" id="cite_ref-medscape_10-0"><a href="#cite_note-medscape-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    

<p>Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases which are characterized by having too many B cells, overactive B cells, or dysfunctional B cells.</p>

<p>Rituximab is used in combination with <a href="Fludarabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fludarabine" title="Fludarabine">fludarabine</a> and <a href="Cyclophosphamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a> to treat previously untreated and previously treated CD20-positive chronic lymphocytic leukemia.<span class="mw-ref" id="cite_ref-Rituxan_label_11-0"><a href="#cite_note-Rituxan_label-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Rituximab is used in combination with <a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">methotrexate</a> to treat moderately-to severely-active rheumatoid arthritis with inadequate response to one or more TNF antagonist therapies.<span class="mw-ref" id="cite_ref-Rituxan_label_11-1"><a href="#cite_note-Rituxan_label-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Rituximab is used in combination with glucocorticoids to treat both granulomatosis with polyangiitis and microscopic polyangiitis.<span class="mw-ref" id="cite_ref-Rituxan_label_11-2"><a href="#cite_note-Rituxan_label-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>

<p>Rituximab in combination with <a href="Hyaluronidase.htm" tppabs="https://ptable.com/wiki/compounds/A/Hyaluronidase" title="Hyaluronidase">hyaluronidase</a> human, sold under the brand names <i>MabThera SC</i> and <i>Rituxan Hycela</i>,<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> is used to treat follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.<span class="mw-ref" id="cite_ref-Rituxan_Hycela_label_13-0"><a href="#cite_note-Rituxan_Hycela_label-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Blood_cancers">Blood cancers</h3></summary>
    

<p>Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and lymphocyte predominant subtype, of Hodgkin's Lymphoma.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> This also includes Waldenström's macroglobulinemia a type of NHL.<span class="mw-ref" id="cite_ref-AHFS2016_3-7"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Autoimmune_diseases">Autoimmune diseases</h3></summary>
    

<p>Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised controlled trials and is now licensed for use in refractory rheumatoid disease.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> In the United States, it has been FDA-approved for use in combination with <a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">methotrexate</a> (MTX) for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti-TNF-alpha therapy. In Europe, the license is slightly more restrictive: it is licensed for use in combination with MTX in patients with severe active RA who have had an inadequate response to one or more anti-TNF therapy.<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>There is some evidence for efficacy, but not necessarily safety, in a range of other autoimmune diseases, and rituximab is widely used off-label to treat difficult cases of multiple sclerosis,<span class="mw-ref" id="cite_ref-McGinley2017rev_17-0"><a href="#cite_note-McGinley2017rev-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy and autoimmune anemias.<span class="mw-ref" id="cite_ref-NWU_19-0"><a href="#cite_note-NWU-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> The most dangerous, although among the most rare, side effect is progressive multifocal leukoencephalopathy (PML) infection, which is usually fatal; however only a very small number of cases have been recorded occurring in autoimmune diseases.<span class="mw-ref" id="cite_ref-NWU_19-1"><a href="#cite_note-NWU-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Other autoimmune diseases that have been treated with rituximab include autoimmune hemolytic anemia, pure red cell aplasia, thrombotic thrombocytopenic purpura (TTP),<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> idiopathic thrombocytopenic purpura (ITP),<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Evans syndrome,<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> vasculitis (e.g., granulomatosis with polyangiitis), bullous skin disorders (for example pemphigus, pemphigoid—with very encouraging results of approximately 85% rapid recovery in pemphigus, according to a 2006 study),<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> type 1 diabetes mellitus, Sjögren syndrome, anti-NMDA receptor encephalitis and Devic's disease,<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> Graves' ophthalmopathy,<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> autoimmune pancreatitis,<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> Opsoclonus myoclonus syndrome (OMS),<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> and IgG4-related disease.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> There is some evidence that it is ineffective in treating IgA-mediated autoimmune diseases.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Organ_transplants">Organ transplants</h3></summary>
    

<p>Rituximab is being used off-label in the management of kidney transplant recipients. This drug may have some utility in transplants involving incompatible blood groups. It is also used as induction therapy in highly sensitized patients going for kidney transplantation. The use of rituximab has not been proven to be efficacious in this setting and like all depleting agents, carries with it the risk of infection.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_events">Adverse events</h2></summary>
    

<p>Serious adverse events, which can cause death and disability, include:<span class="mw-ref" id="cite_ref-Rituxan_label_11-3"><a href="#cite_note-Rituxan_label-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2016_3-8"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<ul><li>Severe infusion reaction.</li>
<li>Cardiac arrest</li>
<li>Cytokine release syndrome</li>
<li>Tumor lysis syndrome, causing acute kidney injury</li>
<li>Infections
<ul><li>Hepatitis B reactivation</li>
<li>Other viral infections</li>
<li>Progressive multifocal leukoencephalopathy (PML) caused by JC virus reactivation<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></li></ul></li>
<li>Immune toxicity, with depletion of B cells in 70% to 80% of lymphoma patients</li>
<li>Pulmonary toxicity<span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></li>
<li>Bowel obstruction and perforation<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></li></ul>

<p>Two patients with systemic lupus erythematosus died of progressive multifocal leukoencephalopathy (PML) after being treated with rituximab. PML is caused by activation of JC virus, a common virus in the brain which is usually latent. Reactivation of the JC virus usually results in death or severe brain damage.<span class="mw-ref" id="cite_ref-urlRituximab_(marketed_as_Rituxan)_Information_35-0"><a href="#cite_note-urlRituximab_(marketed_as_Rituxan)_Information-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span></p>

<p>At least one patient with rheumatoid arthritis developed PML after treatment with rituximab.<span class="mw-ref" id="cite_ref-urlRituximab,_RA_and_PML_36-0"><a href="#cite_note-urlRituximab,_RA_and_PML-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span></p>

<p>Rituximab has been reported as a possible cofactor in a chronic Hepatitis E infection in a person with lymphoma. Hepatitis E infection is normally an acute infection, suggesting the drug in combination with lymphoma may have weakened the body's immune response to the virus.<span class="mw-ref" id="cite_ref-37"><a href="#cite_note-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanisms_of_action">Mechanisms of action</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Rituximab_mechanisms_of_action.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Rituximab_mechanisms_of_action.jpg" data-file-width="659" data-file-height="399" data-file-type="bitmap" height="133" width="220"><div class="thumbcaption" style="text-align: left">Rituximab mechanisms of action; the three major independent mechanisms are (1) antibody dependent cellular cytotoxicity (ADCC), (2) complement mediated cytotoxicity (CMC), and (3) apoptosis; subset panel illustrates a schematic view of CD20 structure and rituximab.<span class="mw-ref" id="cite_ref-pmid26443686_38-0"><a href="#cite_note-pmid26443686-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></div></div></div>
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Rituxan_in_action.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Rituxan_in_action.jpg" data-file-width="478" data-file-height="269" data-file-type="bitmap" height="124" width="220"><div class="thumbcaption" style="text-align: left">Rituximab binding to CD20. The CD20 proteins are sticking out of the cell membrane, and rituximab, the Y-shaped antibody, is binding to the CD20 proteins.</div></div></div>
<p>The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in differentiation, but it is absent on terminally differentiated plasma cells. Although the function of CD20 is unknown, it may play a role in <a href="Calcium.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium" title="Calcium">Ca<sup>2+</sup></a> influx across plasma membranes, maintaining intracellular Ca<sup>2+</sup> concentration and allowing activation of B cells.</p>

<p>Rituximab is relatively ineffective in elimination of cells with low CD20 cell-surface levels. It tends to stick to one side of B cells, where CD20 is, forming a cap and drawing proteins over to that side. The presence of the cap changes the effectiveness of natural killer (NK) cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In contrast, when the B cell lacked this asymmetric protein cluster, it was killed only 40% of the time.<span class="mw-ref" id="cite_ref-39"><a href="#cite_note-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-pmid23613524_40-0"><a href="#cite_note-pmid23613524-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>

<p>The following effects have been found:<span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<ul><li>The Fc portion of rituximab mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</li>
<li>Rituximab has a general regulatory effect on the cell cycle.</li>
<li>It increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen).</li>
<li>It elicits shedding of CD23.</li>
<li>It downregulates the B cell receptor.</li>
<li>It induces apoptosis of CD20+ cells.</li></ul>

<p>The combined effect results in the elimination of B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.</p>

<p>Rituximab binds to amino acids 170-173 and 182-185 on CD20, which are physically close to each other as a result of a disulfide bond between amino acids 167 and 183.<span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Rituximab was developed by researcher Nabil Hanna and coworkers at IDEC Pharmaceuticals under the name IDEC-C2B8. The U.S. patent for the drug was issued in 1998 and expired in 2015.<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>

<p>Based on its safety and effectiveness in clinical trials,<span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> rituximab was approved by the U.S. Food and Drug Administration in 1997 to treat B-cell non-Hodgkin lymphomas resistant to other chemotherapy regimens.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> Rituximab, in combination with CHOP chemotherapy, is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas.<span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> In 2010, it was approved by the European Commission for maintenance treatment after initial treatment of follicular lymphoma.<span class="mw-ref" id="cite_ref-47"><a href="#cite_note-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></p>

<p>Rituximab is currently co-marketed by Biogen and Genentech in the U.S., by Hoffmann-La Roche in Canada and the European Union, Chugai Pharmaceuticals, Zenyaku Kogyo in Japan and AryoGen in Iran.</p>

<p>It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.<span class="mw-ref" id="cite_ref-WHO21st_9-1"><a href="#cite_note-WHO21st-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>In 2014 Genentech reclassified rituxan as a specialty drug, a class of drugs that are only available through specialty distributors in the US.<span class="mw-ref" id="cite_ref-Time_2014_48-0"><a href="#cite_note-Time_2014-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span> Because wholesalers discounts and rebates no longer apply, hospitals would pay more.<span class="mw-ref" id="cite_ref-Time_2014_48-1"><a href="#cite_note-Time_2014-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></p>

<p>Originally available for intravenous injection (e.g. over 2.5 hrs), in 2016 it gained EU approval in a formulation for subcutaneous injection for CLL.<span class="mw-ref" id="cite_ref-49"><a href="#cite_note-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span></p>

<p>Patents on the drug in expired in Europe in February 2013 and in the US in September 2016.<span class="mw-ref" id="cite_ref-GABI_50-0"><a href="#cite_note-GABI-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span> <span>By November 2018</span>, several biosimilars had been approved in the US, India, the European Union, Switzerland, Japan and Australia.<span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-GABI_50-1"><a href="#cite_note-GABI-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Chronic_fatigue_syndrome">Chronic fatigue syndrome</h3></summary>
    
<p>Rituximab did not improve symptoms in patients with chronic fatigue syndrome in a trial published in 2019.<span class="mw-ref" id="cite_ref-:0_53-0"><a href="#cite_note-:0-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> 22% of participants had serious events.<span class="mw-ref" id="cite_ref-:0_53-1"><a href="#cite_note-:0-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> This potential use was investigated after improvements in chronic fatigue syndrome was seen in two cancer patients treated with rituximab.<span class="mw-ref" id="cite_ref-castro20172_55-0"><a href="#cite_note-castro20172-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Intrathecal">Intrathecal</h3></summary>
    

<p>For CNS diseases, rituximab could be administered intrathecally and this possibility is under study.<span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Other_anti-CD20_monoclonals">Other anti-CD20 monoclonals</h3></summary>
    

<p>The efficacy and success of Rituximab has led to some other anti-CD20 monoclonal antibodies being developed:</p>

<ul><li>ocrelizumab, humanized (90%-95% human) B cell-depleting agent.</li>
<li>ofatumumab (HuMax-CD20) a fully human B cell-depleting agent.<span class="mw-ref" id="cite_ref-titleGenmab.com_/_HuMax-CD20_(ofatumumab)_57-0"><a href="#cite_note-titleGenmab.com_/_HuMax-CD20_(ofatumumab)-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span></li>
<li>Third-generation anti-CD20s such as obinutuzumab have a glycoengineered Fc fragment (Fc)<span class="mw-ref" id="cite_ref-titleFc-structure_58-0"><a href="#cite_note-titleFc-structure-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span> with enhanced binding to Fc gamma receptors, which increase ADCC (antibody-dependent cellular cytotoxicity).<span class="mw-ref" id="cite_ref-titleMonoclonal_antibodies_targeting_cancer:_'magic_bullets'_or_just_the_trigger?_59-0"><a href="#cite_note-titleMonoclonal_antibodies_targeting_cancer:_'magic_bullets'_or_just_the_trigger?-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> This strategy for enhancing a monoclonal antibody's ability to induce ADCC takes advantage of the fact that the displayed Fc glycan controls the antibody's affinity for Fc receptors.<span class="mw-ref" id="cite_ref-60"><a href="#cite_note-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span></li></ul>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-generic-1"> <span id="mw-reference-text-cite_note-generic-1" class="mw-reference-text">Drugs.com <a href="javascript:if(confirm('https://www.drugs.com/international/rituximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/rituximab.html'" tppabs="https://www.drugs.com/international/rituximab.html" class="external text external">International brand names for rituximab</a> <a href="javascript:if(confirm('https://web.archive.org/web/20160422111521/http://www.drugs.com/international/rituximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160422111521/http://www.drugs.com/international/rituximab.html'" tppabs="https://web.archive.org/web/20160422111521/http://www.drugs.com/international/rituximab.html" class="external text external">Archived</a> 2016-04-22 at the Wayback Machine Page accessed 1 April 2016</span></li><li id="cite_note-Drugs.com_pregnancy-2"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/rituximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/rituximab.html'" tppabs="https://www.drugs.com/pregnancy/rituximab.html" class="external text external">"Rituximab Use During Pregnancy"</a>. <i>Drugs.com</i>. 16 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">2 February</span> 2020</span>.</cite></span></li><li id="cite_note-AHFS2016-3"> <span id="mw-reference-text-cite_note-AHFS2016-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/rituximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/rituximab.html'" tppabs="https://www.drugs.com/monograph/rituximab.html" class="external text external">"Rituximab"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20160327001117/http://www.drugs.com/monograph/rituximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160327001117/http://www.drugs.com/monograph/rituximab.html'" tppabs="https://web.archive.org/web/20160327001117/http://www.drugs.com/monograph/rituximab.html" class="external text external">Archived</a> from the original on 27 March 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2016</span>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite id="CITEREFTandanHehirWaheedHoward2017" class="citation journal cs1">Tandan, Rup; Hehir, Michael K.; Waheed, Waqar; Howard, Diantha B. (August 2017). "Rituximab treatment of myasthenia gravis: A systematic review". <i>Muscle &amp; Nerve</i>. <b>56</b> (2): 185–196. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fmus.25597  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fmus.25597'" tppabs="https://doi.org/10.1002%2Fmus.25597" class="external text external">10.1002/mus.25597</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1097-4598  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1097-4598'" tppabs="https://www.worldcat.org/issn/1097-4598" class="external text external">1097-4598</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28164324  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28164324'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28164324" class="external text external">28164324</a>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFSingerMcCune2017" class="citation journal cs1">Singer, O; McCune, WJ (May 2017). "Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis". <i>Current Opinion in Rheumatology</i>. <b>29</b> (3): 248–253. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FBOR.0000000000000382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FBOR.0000000000000382'" tppabs="https://doi.org/10.1097%2FBOR.0000000000000382" class="external text external">10.1097/BOR.0000000000000382</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28306595  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28306595'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28306595" class="external text external">28306595</a>.</cite></span></li><li id="cite_note-Doj2018-6"> <span id="mw-reference-text-cite_note-Doj2018-6" class="mw-reference-text"><cite id="CITEREFDojcinovFendQuintanilla-Martinez2018" class="citation journal cs1">Dojcinov SD, Fend F, Quintanilla-Martinez L (March 2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874754  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874754'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874754" class="external text external">"EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts"</a>. <i>Pathogens (Basel, Switzerland)</i>. <b>7</b> (1): 28. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fpathogens7010028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fpathogens7010028'" tppabs="https://doi.org/10.3390%2Fpathogens7010028" class="external text external">10.3390/pathogens7010028</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874754  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874754'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874754" class="external text external">5874754</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29518976  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29518976'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29518976" class="external text external">29518976</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b'" tppabs="http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b" class="external text external">"Boxed Warning and new recommendations to decrease risk of hepatitis B"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 13 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">2 February</span> 2020</span>.</cite></span></li><li id="cite_note-Bos2013-8"> <span id="mw-reference-text-cite_note-Bos2013-8" class="mw-reference-text"><cite id="CITEREFBoschRamos-CasalsKhamashta2013" class="citation book cs1">Bosch, Xavier; Ramos-Casals, Manuel; Khamashta, Munther A. (2013). <a href="javascript:if(confirm('https://books.google.com/books?id=2l-4BAAAQBAJ&pg=PA4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2l-4BAAAQBAJ&pg=PA4'" tppabs="https://books.google.com/books?id=2l-4BAAAQBAJ&pg=PA4" class="external text external"><i>Drugs Targeting B-Cells in Autoimmune Diseases</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>1–4. ISBN<span>&nbsp;</span><bdi>9783034807067</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20171105200138/https://books.google.com/books?id=2l-4BAAAQBAJ&pg=PA4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20171105200138/https://books.google.com/books?id=2l-4BAAAQBAJ&pg=PA4'" tppabs="https://web.archive.org/web/20171105200138/https://books.google.com/books?id=2l-4BAAAQBAJ&pg=PA4" class="external text external">Archived</a> from the original on 5 November 2017.</cite></span></li><li id="cite_note-WHO21st-9"> <span id="mw-reference-text-cite_note-WHO21st-9" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-medscape-10"> <span id="mw-reference-text-cite_note-medscape-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://archive.today/20180315211628/https://www.medscape.com/viewarticle/883511  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.today/20180315211628/https://www.medscape.com/viewarticle/883511'" tppabs="https://archive.today/20180315211628/https://www.medscape.com/viewarticle/883511" class="external text external">"Rituximab Biosimilars Shown to Be Safe and Effective"</a>. <i>www.medscape.com</i>. Archived from <a href="javascript:if(confirm('https://www.medscape.com/viewarticle/883511  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medscape.com/viewarticle/883511'" tppabs="https://www.medscape.com/viewarticle/883511" class="external text external">the original</a> on 15 March 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">29 November</span> 2017</span>.</cite></span></li><li id="cite_note-Rituxan_label-11"> <span id="mw-reference-text-cite_note-Rituxan_label-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563" class="external text external">"Rituxan- rituximab injection, solution"</a>. <i>DailyMed</i>. 6 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">2 February</span> 2020</span>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.roche.com/products/product-details.htm?productId=8abc3f49-f39f-4c6e-93ae-235c95c7efc6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.roche.com/products/product-details.htm?productId=8abc3f49-f39f-4c6e-93ae-235c95c7efc6'" tppabs="https://www.roche.com/products/product-details.htm?productId=8abc3f49-f39f-4c6e-93ae-235c95c7efc6" class="external text external">"MabThera SC / Rituxan Hycela (rituximab hyaluronidase)"</a>. <i>Roche</i><span class="reference-accessdate">. Retrieved <span class="nowrap">9 August</span> 2020</span>.</cite></span></li><li id="cite_note-Rituxan_Hycela_label-13"> <span id="mw-reference-text-cite_note-Rituxan_Hycela_label-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5b7e82-f018-4eaf-ae78-d6145a906b20  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5b7e82-f018-4eaf-ae78-d6145a906b20'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5b7e82-f018-4eaf-ae78-d6145a906b20" class="external text external">"Rituxan Hycela- rituximab and hyaluronidase injection, solution"</a>. <i>DailyMed</i>. 3 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">2 February</span> 2020</span>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFSainiAzim_HA_JrCocorocchioVanazzi2011" class="citation journal cs1">Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA (2011). "Rituximab in Hodgkin lymphoma: Is the target always a hit?". <i>Cancer Treat Rev</i>. <b>37</b> (5): 385–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ctrv.2010.11.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ctrv.2010.11.005'" tppabs="https://doi.org/10.1016%2Fj.ctrv.2010.11.005" class="external text external">10.1016/j.ctrv.2010.11.005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21183282  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21183282'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21183282" class="external text external">21183282</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFEdwardsSzczepanskiSzechinskiFilipowicz-Sosnowska2004" class="citation journal cs1">Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, Stevens R, Shaw T (2004). <a href="javascript:if(confirm('https://doi.org/10.1056/NEJMoa032534  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056/NEJMoa032534'" tppabs="https://doi.org/10.1056/NEJMoa032534" class="external text external">"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis"</a>. <i>N Engl J Med</i>. <b>350</b> (25): 2572–81. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa032534  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa032534'" tppabs="https://doi.org/10.1056%2FNEJMoa032534" class="external text external">10.1056/NEJMoa032534</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15201414  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15201414'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15201414" class="external text external">15201414</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite id="CITEREFTakKalden2011" class="citation journal cs1">Tak PP, Kalden JR (2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123966" class="external text external">"Advances in rheumatology: new targeted therapeutics"</a>. <i>Arthritis Research &amp; Therapy</i>. <b>13</b> (Suppl 1): S5. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F1478-6354-13-S1-S5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F1478-6354-13-S1-S5'" tppabs="https://doi.org/10.1186%2F1478-6354-13-S1-S5" class="external text external">10.1186/1478-6354-13-S1-S5</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123966" class="external text external">3123966</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21624184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21624184'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21624184" class="external text external">21624184</a>.</cite></span></li><li id="cite_note-McGinley2017rev-17"> <span id="mw-reference-text-cite_note-McGinley2017rev-17" class="mw-reference-text"><cite id="CITEREFMcGinleyMossCohen2017" class="citation journal cs1">McGinley, MP; Moss, BP; Cohen, JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis". <i>Expert Opinion on Drug Safety</i>. <b>16</b> (1): 89–100. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F14740338.2017.1250881  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F14740338.2017.1250881'" tppabs="https://doi.org/10.1080%2F14740338.2017.1250881" class="external text external">10.1080/14740338.2017.1250881</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27756172  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27756172'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27756172" class="external text external">27756172</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFHeGuoZhangZhang2013" class="citation journal cs1">He, Dian; Guo, Rui; Zhang, Fubo; Zhang, Chao; Dong, Shuai; Zhou, Hongyu (6 December 2013). "Rituximab for relapsing-remitting multiple sclerosis". <i>The Cochrane Database of Systematic Reviews</i> (12): CD009130. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD009130.pub3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD009130.pub3'" tppabs="https://doi.org/10.1002%2F14651858.CD009130.pub3" class="external text external">10.1002/14651858.CD009130.pub3</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24310855  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24310855'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24310855" class="external text external">24310855</a>.</cite></span></li><li id="cite_note-NWU-19"> <span id="mw-reference-text-cite_note-NWU-19" class="mw-reference-text"><cite id="CITEREFPaul2009" class="citation web cs1">Paul, Marla (20 May 2009). <a href="javascript:if(confirm('http://www.northwestern.edu/newscenter/stories/2009/05/bennett.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.northwestern.edu/newscenter/stories/2009/05/bennett.html'" tppabs="http://www.northwestern.edu/newscenter/stories/2009/05/bennett.html" class="external text external">"Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus"</a>. Northwestern University News and Information. <a href="javascript:if(confirm('https://web.archive.org/web/20100529073721/http://www.northwestern.edu/newscenter/stories/2009/05/bennett.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100529073721/http://www.northwestern.edu/newscenter/stories/2009/05/bennett.html'" tppabs="https://web.archive.org/web/20100529073721/http://www.northwestern.edu/newscenter/stories/2009/05/bennett.html" class="external text external">Archived</a> from the original on 29 May 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">22 May</span> 2009</span>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090513023924/https://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090513023924/https://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html'" tppabs="https://web.archive.org/web/20090513023924/https://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html" class="external text external">"FDA Warns of Safety Concern Regarding Rituxan in New Patient Population"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 18 December 2006. Archived from <a href="javascript:if(confirm('https://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html'" tppabs="https://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html" class="external text external">the original</a> on 13 May 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">29 April</span> 2013</span>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFFroissartVeyradierHiéBenhamou2015" class="citation journal cs1">Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P (August 2015). <a href="javascript:if(confirm('https://doi.org/10.1016/j.ejim.2015.07.021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.ejim.2015.07.021'" tppabs="https://doi.org/10.1016/j.ejim.2015.07.021" class="external text external">"Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story"</a>. <i>Eur J Intern Med</i>. <b>26</b> (9): 659–65. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejim.2015.07.021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejim.2015.07.021'" tppabs="https://doi.org/10.1016%2Fj.ejim.2015.07.021" class="external text external">10.1016/j.ejim.2015.07.021</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26293834  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26293834'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26293834" class="external text external">26293834</a>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite id="CITEREFBraendstrupBjerrumNielsen2005" class="citation journal cs1">Braendstrup P, Bjerrum OW, Nielsen OJ,  et al. (April 2005). "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura". <i>Am. J. Hematol</i>. <b>78</b> (4): 275–80. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fajh.20276  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fajh.20276'" tppabs="https://doi.org/10.1002%2Fajh.20276" class="external text external">10.1002/ajh.20276</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15795920  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15795920'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15795920" class="external text external">15795920</a>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFPatelMihatovCooperStasi2007" class="citation journal cs1">Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2007). <a href="javascript:if(confirm('https://web.archive.org/web/20070929061010/http://www.communityoncology.net/journal/articles/0402107.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070929061010/http://www.communityoncology.net/journal/articles/0402107.pdf'" tppabs="https://web.archive.org/web/20070929061010/http://www.communityoncology.net/journal/articles/0402107.pdf" class="external text external">"Long-term responses seen with rituximab in patients with ITP"</a> <span class="cs1-format">(PDF)</span>. <i>Community Oncology</i>. <b>4</b> (2): 107. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs1548-5315%2811%2970061-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs1548-5315%2811%2970061-4'" tppabs="https://doi.org/10.1016%2Fs1548-5315%2811%2970061-4" class="external text external">10.1016/s1548-5315(11)70061-4</a>. Archived from <a href="javascript:if(confirm('http://www.communityoncology.net/journal/articles/0402107.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.communityoncology.net/journal/articles/0402107.pdf'" tppabs="http://www.communityoncology.net/journal/articles/0402107.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 29 September 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">18 April</span> 2007</span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFShanafeltMaduemeWoldTefferi2003" class="citation journal cs1">Shanafelt TD, Madueme HL, Wold RC, Tefferi A (2003). <a href="javascript:if(confirm('https://web.archive.org/web/20060313055117/http://www.mayoclinicproceedings.com/pdf/7811/7811a3.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20060313055117/http://www.mayoclinicproceedings.com/pdf/7811/7811a3.pdf'" tppabs="https://web.archive.org/web/20060313055117/http://www.mayoclinicproceedings.com/pdf/7811/7811a3.pdf" class="external text external">"Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome"</a> <span class="cs1-format">(PDF)</span>. <i>Mayo Clinic Proceedings</i>. <b>78</b> (11): 1340–1346. doi:<a href="javascript:if(confirm('https://doi.org/10.4065%2F78.11.1340  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4065%2F78.11.1340'" tppabs="https://doi.org/10.4065%2F78.11.1340" class="external text external">10.4065/78.11.1340</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14601692  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14601692'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14601692" class="external text external">14601692</a>. Archived from <a href="javascript:if(confirm('http://www.mayoclinicproceedings.com/pdf/7811/7811a3.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mayoclinicproceedings.com/pdf/7811/7811a3.pdf'" tppabs="http://www.mayoclinicproceedings.com/pdf/7811/7811a3.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 13 March 2006.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFA._Razzaque_Ahmed,_M.D.Zachary_Spigelman,_M.D.Lisa_A._Cavacini,_Ph.D.Marshall_R._Posner,_M.D.2006" class="citation journal cs1">A. Razzaque Ahmed, M.D.; Zachary Spigelman, M.D.; Lisa A. Cavacini, Ph.D.; Marshall R. Posner, M.D. (26 October 2006). <a href="javascript:if(confirm('https://doi.org/10.1056/nejmoa062930  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056/nejmoa062930'" tppabs="https://doi.org/10.1056/nejmoa062930" class="external text external">"Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin"</a>. <i>N Engl J Med</i>. <b>355</b> (17): 1772–1779. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1056%2Fnejmoa062930  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2Fnejmoa062930'" tppabs="https://doi.org/10.1056%2Fnejmoa062930" class="external text external">10.1056/nejmoa062930</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17065638  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17065638'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17065638" class="external text external">17065638</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFJacobWeinshenkerViolichMcLinskey2008" class="citation journal cs1">Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA (2008). <a href="javascript:if(confirm('https://doi.org/10.1001/archneur.65.11.noc80069  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/archneur.65.11.noc80069'" tppabs="https://doi.org/10.1001/archneur.65.11.noc80069" class="external text external">"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients"</a>. <i>Arch Neurol</i>. <b>65</b> (11): 1443–1448. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Farchneur.65.11.noc80069  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchneur.65.11.noc80069'" tppabs="https://doi.org/10.1001%2Farchneur.65.11.noc80069" class="external text external">10.1001/archneur.65.11.noc80069</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18779415  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18779415'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18779415" class="external text external">18779415</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ophthalmologyjournaloftheaao.com/article/S0161-6420%2809%2900548-X/abstract  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ophthalmologyjournaloftheaao.com/article/S0161-6420%2809%2900548-X/abstract'" tppabs="http://www.ophthalmologyjournaloftheaao.com/article/S0161-6420%2809%2900548-X/abstract" class="external text external">"Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20170822220531/http://www.ophthalmologyjournaloftheaao.com/article/S0161-6420(09)00548-X/abstract  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170822220531/http://www.ophthalmologyjournaloftheaao.com/article/S0161-6420(09)00548-X/abstract'" tppabs="https://web.archive.org/web/20170822220531/http://www.ophthalmologyjournaloftheaao.com/article/S0161-6420(09)00548-X/abstract" class="external text external">Archived</a> from the original on 22 August 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">19 October</span> 2011</span>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite class="citation journal cs1"><a href="javascript:if(confirm('http://www.pancreapedia.org/reviews/immunomodulators-and-rituximab-in-management-of-autoimmune-pancreatitis  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pancreapedia.org/reviews/immunomodulators-and-rituximab-in-management-of-autoimmune-pancreatitis'" tppabs="http://www.pancreapedia.org/reviews/immunomodulators-and-rituximab-in-management-of-autoimmune-pancreatitis" class="external text external">"Immunomodulators and Rituximab in the Management of Autoimmune Pancreatitis"</a>. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.3998%2Fpanc.2013.20  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3998%2Fpanc.2013.20'" tppabs="https://doi.org/10.3998%2Fpanc.2013.20" class="external text external">10.3998/panc.2013.20</a></span>. <a href="javascript:if(confirm('https://web.archive.org/web/20140502010340/http://www.pancreapedia.org/reviews/immunomodulators-and-rituximab-in-management-of-autoimmune-pancreatitis  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140502010340/http://www.pancreapedia.org/reviews/immunomodulators-and-rituximab-in-management-of-autoimmune-pancreatitis'" tppabs="https://web.archive.org/web/20140502010340/http://www.pancreapedia.org/reviews/immunomodulators-and-rituximab-in-management-of-autoimmune-pancreatitis" class="external text external">Archived</a> from the original on 2 May 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">30 April</span> 2014</span>.</cite><span> </span><span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFPranzatelli2004" class="citation journal cs1">Pranzatelli, M. R. (2004). <a href="javascript:if(confirm('https://doi.org/10.1542/peds.2004-0845  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542/peds.2004-0845'" tppabs="https://doi.org/10.1542/peds.2004-0845" class="external text external">"Immunologic and Clinical Responses to Rituximab in a Child with Opsoclonus-Myoclonus Syndrome"</a>. <i>Pediatrics</i>. <b>115</b> (1): e115–9. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1542%2Fpeds.2004-0845  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542%2Fpeds.2004-0845'" tppabs="https://doi.org/10.1542%2Fpeds.2004-0845" class="external text external">10.1542/peds.2004-0845</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15601813  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15601813'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15601813" class="external text external">15601813</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFKhosroshahiWallaceCroweAkamizu2015" class="citation journal cs1">Khosroshahi, A.; Wallace, Z. S.; Crowe, J. L.; Akamizu, T.; Azumi, A.; Carruthers, M. N.; Chari, S. T.; Della-Torre, E.; Frulloni, L.; Goto, H.; Hart, P. A.; Kamisawa, T.; Kawa, S.; Kawano, M.; Kim, M. H.; Kodama, Y.; Kubota, K.; Lerch, M. M.; Löhr, M.; Masaki, Y.; Matsui, S.; Mimori, T.; Nakamura, S.; Nakazawa, T.; Ohara, H.; Okazaki, K.; Ryu, J.H.; Saeki, T.; Schleinitz, N.;  et al. (2015). "International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease". <i>Arthritis &amp; Rheumatology</i>. <b>67</b> (7): 1688–1699. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fart.39132  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fart.39132'" tppabs="https://doi.org/10.1002%2Fart.39132" class="external text external">10.1002/art.39132</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25809420  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25809420'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25809420" class="external text external">25809420</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite id="CITEREFHeShimodaOnoVillalobos2015" class="citation journal cs1">He Y, Shimoda M, Ono Y, Villalobos IB, Mitra A, Konia T, Grando SA, Zone JJ, Maverakis E (2015). <a href="javascript:if(confirm('https://doi.org/10.1001/jamadermatol.2015.59  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/jamadermatol.2015.59'" tppabs="https://doi.org/10.1001/jamadermatol.2015.59" class="external text external">"Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab"</a>. <i>JAMA Dermatol</i>. <b>151</b> (6): 646–50. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Fjamadermatol.2015.59  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjamadermatol.2015.59'" tppabs="https://doi.org/10.1001%2Fjamadermatol.2015.59" class="external text external">10.1001/jamadermatol.2015.59</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25901938  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25901938'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25901938" class="external text external">25901938</a>.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite id="CITEREFMolloyCalabrese2012" class="citation journal cs1">Molloy, Eamonn S.; Calabrese, Leonard H. (2012). "Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies". <i>Arthritis &amp; Rheumatism</i>. <b>64</b> (9): 3043–3051. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fart.34468  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fart.34468'" tppabs="https://doi.org/10.1002%2Fart.34468" class="external text external">10.1002/art.34468</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22422012  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22422012'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22422012" class="external text external">22422012</a>.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite id="CITEREFBurtonKaczmarskiJan-Mohamed2003" class="citation journal cs1">Burton C, Kaczmarski R, Jan-Mohamed R (2003). "Interstitial pneumonitis related to rituximab therapy". <i>N Engl J Med</i>. <b>348</b> (26): 2690–1, discussion 2690–1. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM200306263482619  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM200306263482619'" tppabs="https://doi.org/10.1056%2FNEJM200306263482619" class="external text external">10.1056/NEJM200306263482619</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12826649  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12826649'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12826649" class="external text external">12826649</a>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20140327221239/http://rochecanada.com/portal/servlet/staticfilesServlet?type=data&communityId=re753001&id=static%2Fattachedfile%2Fre7300002%2Fre77300002%2FAttachedFile_04801.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140327221239/http://rochecanada.com/portal/servlet/staticfilesServlet?type=data&communityId=re753001&id=static%2Fattachedfile%2Fre7300002%2Fre77300002%2FAttachedFile_04801.pdf'" tppabs="https://web.archive.org/web/20140327221239/http://rochecanada.com/portal/servlet/staticfilesServlet?type=data&communityId=re753001&id=static%2Fattachedfile%2Fre7300002%2Fre77300002%2FAttachedFile_04801.pdf" class="external text external">"Reports of Bowel Obstruction and Perforation with RITUXAN (rituximab)"</a> <span class="cs1-format">(PDF)</span>. Roche Canada. 10 November 2006. Archived from <a href="javascript:if(confirm('http://rochecanada.com/portal/servlet/staticfilesServlet?type=data&communityId=re753001&id=static/attachedfile/re7300002/re77300002/AttachedFile_04801.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://rochecanada.com/portal/servlet/staticfilesServlet?type=data&communityId=re753001&id=static/attachedfile/re7300002/re77300002/AttachedFile_04801.pdf'" tppabs="http://rochecanada.com/portal/servlet/staticfilesServlet?type=data&communityId=re753001&id=static/attachedfile/re7300002/re77300002/AttachedFile_04801.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 27 March 2014.</cite></span></li><li id="cite_note-urlRituximab_(marketed_as_Rituxan)_Information-35"> <span id="mw-reference-text-cite_note-urlRituximab_(marketed_as_Rituxan)_Information-35" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rituximab-marketed-rituxan-information  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rituximab-marketed-rituxan-information'" tppabs="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rituximab-marketed-rituxan-information" class="external text external">"Rituximab (marketed as Rituxan) Information"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 23 July 2015. <a href="javascript:if(confirm('https://web.archive.org/web/20091115233717/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109106.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20091115233717/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109106.htm'" tppabs="https://web.archive.org/web/20091115233717/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109106.htm" class="external text external">Archived</a> from the original on 15 November 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">15 November</span> 2009</span>.</cite></span></li><li id="cite_note-urlRituximab,_RA_and_PML-36"> <span id="mw-reference-text-cite_note-urlRituximab,_RA_and_PML-36" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20080916215120/https://www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080916215120/https://www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf'" tppabs="https://web.archive.org/web/20080916215120/https://www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf" class="external text external">"Rituximab, RA and PML"</a> <span class="cs1-format">(PDF)</span>. <i>U.S. Food and Drug Administration (FDA)</i>. Archived from <a href="javascript:if(confirm('https://www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf'" tppabs="https://www.fda.gov/medwatch/safety/2008/rituxan_DHCP_Final%209411700.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 16 September 2008<span class="reference-accessdate">. Retrieved <span class="nowrap">14 September</span> 2008</span>.</cite></span></li><li id="cite_note-37"> <span id="mw-reference-text-cite_note-37" class="mw-reference-text"><cite id="CITEREFKriston2009" class="citation journal cs1">Kriston, Levente (2009). "Challenges in Reporting Meta-analyses of Diagnostic Accuracy Studies". <i>Annals of Internal Medicine</i>. <b>150</b> (6): 430. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-150-6-200903170-00025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-150-6-200903170-00025'" tppabs="https://doi.org/10.7326%2F0003-4819-150-6-200903170-00025" class="external text external">10.7326/0003-4819-150-6-200903170-00025</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19293085  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19293085'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19293085" class="external text external">19293085</a>.</cite></span></li><li id="cite_note-pmid26443686-38"> <span id="mw-reference-text-cite_note-pmid26443686-38" class="mw-reference-text"><cite id="CITEREFSeyfizadehSeyfizadeh,_NayerHasenkamp,_JHuerta-Yepez,_S2016" class="citation journal cs1">Seyfizadeh, Narges; Seyfizadeh, Nayer; Hasenkamp, J; Huerta-Yepez, S (2016). "A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections". <i>Crit Rev Oncol Hematol</i>. <b>97</b>: 275–290. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.critrevonc.2015.09.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.critrevonc.2015.09.001'" tppabs="https://doi.org/10.1016%2Fj.critrevonc.2015.09.001" class="external text external">10.1016/j.critrevonc.2015.09.001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26443686  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26443686'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26443686" class="external text external">26443686</a>.</cite></span></li><li id="cite_note-39"> <span id="mw-reference-text-cite_note-39" class="mw-reference-text"><cite id="CITEREFRudnickaOszmianaFinchStrickland2013" class="citation journal cs1">Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I.; Schofield, D. J.; Lowe, D. C.; Sleeman, M. A.; Davis, D. M. (2013). <a href="javascript:if(confirm('http://www.kurzweilai.net/scientists-discover-why-a-specific-cancer-drug-is-so-effective  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.kurzweilai.net/scientists-discover-why-a-specific-cancer-drug-is-so-effective'" tppabs="http://www.kurzweilai.net/scientists-discover-why-a-specific-cancer-drug-is-so-effective" class="external text external">"Scientists discover why a specific cancer drug is so effective"</a>. <i>Blood</i>. <b>121</b> (23): 4694–4702. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood-2013-02-482570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood-2013-02-482570'" tppabs="https://doi.org/10.1182%2Fblood-2013-02-482570" class="external text external">10.1182/blood-2013-02-482570</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23613524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23613524'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23613524" class="external text external">23613524</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20130503033228/http://www.kurzweilai.net/scientists-discover-why-a-specific-cancer-drug-is-so-effective  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130503033228/http://www.kurzweilai.net/scientists-discover-why-a-specific-cancer-drug-is-so-effective'" tppabs="https://web.archive.org/web/20130503033228/http://www.kurzweilai.net/scientists-discover-why-a-specific-cancer-drug-is-so-effective" class="external text external">Archived</a> from the original on 3 May 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">29 April</span> 2013</span>.</cite></span></li><li id="cite_note-pmid23613524-40"> <span id="mw-reference-text-cite_note-pmid23613524-40" class="mw-reference-text"><cite class="citation journal cs1">Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I.; Schofield, D. J.; Lowe, D. C.; Sleeman, M. A.; Davis, D. M. (2013). <a href="javascript:if(confirm('https://doi.org/10.1182/blood-2013-02-482570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182/blood-2013-02-482570'" tppabs="https://doi.org/10.1182/blood-2013-02-482570" class="external text external">"Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity"</a>. <i>Blood</i>. <b>121</b> (23): 4694–4702. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood-2013-02-482570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood-2013-02-482570'" tppabs="https://doi.org/10.1182%2Fblood-2013-02-482570" class="external text external">10.1182/blood-2013-02-482570</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23613524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23613524'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23613524" class="external text external">23613524</a>.</cite></span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite id="CITEREFShaw2003" class="citation journal cs1">Shaw, T. (2003). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766758  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766758'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766758" class="external text external">"B cell therapy for rheumatoid arthritis: The rituximab (anti-CD20) experience"</a>. <i>Annals of the Rheumatic Diseases</i>. <b>62</b> (90002): 55ii–59. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fard.62.suppl_2.ii55  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fard.62.suppl_2.ii55'" tppabs="https://doi.org/10.1136%2Fard.62.suppl_2.ii55" class="external text external">10.1136/ard.62.suppl_2.ii55</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766758  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766758'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766758" class="external text external">1766758</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14532151  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14532151'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14532151" class="external text external">14532151</a>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite id="CITEREFBinder_M,_Otto_F,_Mertelsmann_R,_Veelken_H,_Trepel_M.2006" class="citation journal cs1">Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. (2006). <a href="javascript:if(confirm('https://doi.org/10.1182/blood-2006-04-014639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182/blood-2006-04-014639'" tppabs="https://doi.org/10.1182/blood-2006-04-014639" class="external text external">"The epitope recognized by rituximab"</a>. <i>Blood</i>. <b>108</b> (6): 1975–1978. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood-2006-04-014639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood-2006-04-014639'" tppabs="https://doi.org/10.1182%2Fblood-2006-04-014639" class="external text external">10.1182/blood-2006-04-014639</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16705086  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16705086'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16705086" class="external text external">16705086</a>.</cite><span class="cs1-maint citation-comment">CS1 maint: multiple names: authors list (link)</span></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><a href="javascript:if(confirm('http://www.drugbank.ca/drugs/DB00073  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.drugbank.ca/drugs/DB00073'" tppabs="http://www.drugbank.ca/drugs/DB00073" class="external text external">DrugBank DB00073</a> <a href="javascript:if(confirm('https://web.archive.org/web/20140105002750/http://www.drugbank.ca/drugs/DB00073  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140105002750/http://www.drugbank.ca/drugs/DB00073'" tppabs="https://web.archive.org/web/20140105002750/http://www.drugbank.ca/drugs/DB00073" class="external text external">Archived</a><span> 2014-01-05 at the </span>Wayback Machine</span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite id="CITEREFMaloneyGrillo-LópezWhite1997" class="citation journal cs1">Maloney DG, Grillo-López AJ, White CA,  et al. (September 1997). <a href="javascript:if(confirm('http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=9310469  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=9310469'" tppabs="http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=9310469" class="external text external">"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma"</a>. <i>Blood</i>. <b>90</b> (6): 2188–95. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood.V90.6.2188  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood.V90.6.2188'" tppabs="https://doi.org/10.1182%2Fblood.V90.6.2188" class="external text external">10.1182/blood.V90.6.2188</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9310469  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9310469'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9310469" class="external text external">9310469</a>.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite id="CITEREFScott1998" class="citation journal cs1">Scott, Shane D. (1998). "Rituximab: A New Therapeutic Monoclonal Antibody for Non-Hodgkin's Lymphoma". <i>Cancer Practice</i>. <b>6</b> (3): 195–197. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1523-5394.1998.006003195.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1523-5394.1998.006003195.x'" tppabs="https://doi.org/10.1046%2Fj.1523-5394.1998.006003195.x" class="external text external">10.1046/j.1523-5394.1998.006003195.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9652253  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9652253'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9652253" class="external text external">9652253</a>.</cite></span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text"><i>Harrison's Principles of Internal Medicine</i>, Longo et al. <i>McGraw Hill Medical</i> 2011 page 931</span></li><li id="cite_note-47"> <span id="mw-reference-text-cite_note-47" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/'" tppabs="http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/" class="external text external">"Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy"</a>. 29 October 2010. <a href="javascript:if(confirm('https://web.archive.org/web/20101031202519/http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20101031202519/http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/'" tppabs="https://web.archive.org/web/20101031202519/http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/" class="external text external">Archived</a> from the original on 31 October 2010.</cite></span></li><li id="cite_note-Time_2014-48"> <span id="mw-reference-text-cite_note-Time_2014-48" class="mw-reference-text"><cite id="CITEREFSaporito,_Bill2014" class="citation web cs1">Saporito, Bill (27 October 2014). <a href="javascript:if(confirm('http://time.com/3541484/cancer-drug-price-hikes/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://time.com/3541484/cancer-drug-price-hikes/'" tppabs="http://time.com/3541484/cancer-drug-price-hikes/" class="external text external">"Hospitals Furious at Cancer-Drug Price Hikes"</a>. <i>Time</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20151020062334/http://time.com/3541484/cancer-drug-price-hikes/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151020062334/http://time.com/3541484/cancer-drug-price-hikes/'" tppabs="https://web.archive.org/web/20151020062334/http://time.com/3541484/cancer-drug-price-hikes/" class="external text external">Archived</a> from the original on 20 October 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">26 October</span> 2015</span>.</cite></span></li><li id="cite_note-49"> <span id="mw-reference-text-cite_note-49" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.biopharma-reporter.com/Bio-Developments/EU-approves-indication-for-subcutaneous-form-of-Roche-s-MabThera/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.biopharma-reporter.com/Bio-Developments/EU-approves-indication-for-subcutaneous-form-of-Roche-s-MabThera/'" tppabs="http://www.biopharma-reporter.com/Bio-Developments/EU-approves-indication-for-subcutaneous-form-of-Roche-s-MabThera/" class="external text external">"EU approves second indication for subcutaneous form of Roche's rituximab"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160607225341/http://www.biopharma-reporter.com/Bio-Developments/EU-approves-indication-for-subcutaneous-form-of-Roche-s-MabThera  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160607225341/http://www.biopharma-reporter.com/Bio-Developments/EU-approves-indication-for-subcutaneous-form-of-Roche-s-MabThera'" tppabs="https://web.archive.org/web/20160607225341/http://www.biopharma-reporter.com/Bio-Developments/EU-approves-indication-for-subcutaneous-form-of-Roche-s-MabThera" class="external text external">Archived</a> from the original on 7 June 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">9 June</span> 2016</span>.</cite></span></li><li id="cite_note-GABI-50"> <span id="mw-reference-text-cite_note-GABI-50" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab'" tppabs="http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab" class="external text external">"Biosimilars of Rituximab"</a>. Generics and Biosimilars Initiative. 14 April 2017. <a href="javascript:if(confirm('https://web.archive.org/web/20170331230914/http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170331230914/http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab'" tppabs="https://web.archive.org/web/20170331230914/http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab" class="external text external">Archived</a> from the original on 31 March 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">29 April</span> 2017</span>.</cite></span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-adult-patients-non-hodgkins-lymphoma  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-adult-patients-non-hodgkins-lymphoma'" tppabs="https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-adult-patients-non-hodgkins-lymphoma" class="external text external">"FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 28 November 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">11 November</span> 2019</span>.</cite></span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><cite id="CITEREFLahiriOsterman2018" class="citation news cs1">Lahiri, Diptendu; Osterman, Cynthia (2 November 2018). <a href="javascript:if(confirm('https://www.reuters.com/article/us-novartis-rituximab/novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab-idUSKCN1N72NA  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/us-novartis-rituximab/novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab-idUSKCN1N72NA'" tppabs="https://www.reuters.com/article/us-novartis-rituximab/novartis-abandons-effort-for-u-s-approval-of-biosimilar-rituximab-idUSKCN1N72NA" class="external text external">"Novartis abandons effort for U.S. approval of biosimilar rituximab"</a>. Reuters<span class="reference-accessdate">. Retrieved <span class="nowrap">3 November</span> 2018</span>.</cite></span></li><li id="cite_note-:0-53"> <span id="mw-reference-text-cite_note-:0-53" class="mw-reference-text"><cite id="CITEREFFlugeRekelandLienThürmer2019" class="citation journal cs1">Fluge, Øystein; Rekeland, Ingrid G.; Lien, Katarina; Thürmer, Hanne; Borchgrevink, Petter C.; Schäfer, Christoph; Sørland, Kari; Aßmus, Jörg; Ktoridou-Valen, Irini (2 April 2019). "B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial". <i>Annals of Internal Medicine</i>. <b>170</b> (9): 585–593. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2FM18-1451  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2FM18-1451'" tppabs="https://doi.org/10.7326%2FM18-1451" class="external text external">10.7326/M18-1451</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0003-4819  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0003-4819'" tppabs="https://www.worldcat.org/issn/0003-4819" class="external text external">0003-4819</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30934066  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30934066'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30934066" class="external text external">30934066</a>.</cite></span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text"><cite id="CITEREFTucker2019" class="citation web cs1">Tucker, Miriam E. (2 April 2019). <span class="cs1-lock-registration"><a href="javascript:if(confirm('https://www.medscape.com/viewarticle/911197  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medscape.com/viewarticle/911197'" tppabs="https://www.medscape.com/viewarticle/911197" class="external text external">"Rituximab Fails to Improve Symptoms in ME/CFS"</a></span>. <i>Medscape</i>.</cite></span></li><li id="cite_note-castro20172-55"> <span id="mw-reference-text-cite_note-castro20172-55" class="mw-reference-text"><cite id="CITEREFCastro-MarreroSáez-FrancàsSantilloAlegre2017" class="citation journal cs1">Castro-Marrero, Jesus; Sáez-Francàs, Naia; Santillo, Dafna; Alegre, Jose (2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301046  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301046'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301046" class="external text external">"Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: All roads lead to Rome"</a>. <i>British Journal of Pharmacology</i>. <b>174</b> (5): 345–369. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fbph.13702  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fbph.13702'" tppabs="https://doi.org/10.1111%2Fbph.13702" class="external text external">10.1111/bph.13702</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301046  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301046'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301046" class="external text external">5301046</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28052319  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28052319'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28052319" class="external text external">28052319</a>.</cite></span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text"><cite id="CITEREFBonnanFerrariBertandeauDemasles2014" class="citation journal cs1">Bonnan, M; Ferrari, S; Bertandeau, E; Demasles, S; Krim, E; Miquel, M; Barroso, B (2014). "Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials". <i>Current Drug Targets</i>. <b>15</b> (13): 1205–14. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F1389450115666141029234644  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F1389450115666141029234644'" tppabs="https://doi.org/10.2174%2F1389450115666141029234644" class="external text external">10.2174/1389450115666141029234644</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25355180  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25355180'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25355180" class="external text external">25355180</a>.</cite></span></li><li id="cite_note-titleGenmab.com_/_HuMax-CD20_(ofatumumab)-57"> <span id="mw-reference-text-cite_note-titleGenmab.com_/_HuMax-CD20_(ofatumumab)-57" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20070911144653/http://www.genmab.com/ScienceAndResearch/ProductsinDevelopment/HuMax-CD20.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070911144653/http://www.genmab.com/ScienceAndResearch/ProductsinDevelopment/HuMax-CD20.aspx'" tppabs="https://web.archive.org/web/20070911144653/http://www.genmab.com/ScienceAndResearch/ProductsinDevelopment/HuMax-CD20.aspx" class="external text external">"Genmab.com / HuMax-CD20 (ofatumumab)"</a>. Archived from <a href="javascript:if(confirm('http://www.genmab.com/ScienceAndResearch/ProductsinDevelopment/HuMax-CD20.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genmab.com/ScienceAndResearch/ProductsinDevelopment/HuMax-CD20.aspx'" tppabs="http://www.genmab.com/ScienceAndResearch/ProductsinDevelopment/HuMax-CD20.aspx" class="external text external">the original</a> on 11 September 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">3 December</span> 2007</span>.</cite></span></li><li id="cite_note-titleFc-structure-58"> <span id="mw-reference-text-cite_note-titleFc-structure-58" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.healthvalue.net/Fc-structure.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.healthvalue.net/Fc-structure.html'" tppabs="http://www.healthvalue.net/Fc-structure.html" class="external text external">"Fc-structure"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20071110011928/http://www.healthvalue.net/Fc-structure.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20071110011928/http://www.healthvalue.net/Fc-structure.html'" tppabs="https://web.archive.org/web/20071110011928/http://www.healthvalue.net/Fc-structure.html" class="external text external">Archived</a> from the original on 10 November 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">3 December</span> 2007</span>.</cite></span></li><li id="cite_note-titleMonoclonal_antibodies_targeting_cancer:_'magic_bullets'_or_just_the_trigger?-59"> <span id="mw-reference-text-cite_note-titleMonoclonal_antibodies_targeting_cancer:_'magic_bullets'_or_just_the_trigger?-59" class="mw-reference-text"><cite id="CITEREFEccles2001" class="citation journal cs1">Eccles, SA (2001). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138676  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138676'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138676" class="external text external">"Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?"</a>. <i>Breast Cancer Research</i>. <b>3</b> (2): 86–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2Fbcr276  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2Fbcr276'" tppabs="https://doi.org/10.1186%2Fbcr276" class="external text external">10.1186/bcr276</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138676  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138676'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138676" class="external text external">138676</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11250751  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11250751'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11250751" class="external text external">11250751</a>.</cite></span></li><li id="cite_note-60"> <span id="mw-reference-text-cite_note-60" class="mw-reference-text"><cite id="CITEREFMaverakisKimShimodaGershwin2015" class="citation journal cs1">Maverakis E, Kim K, Shimoda M, Gershwin M, Patel F, Wilken R, Raychaudhuri S, Ruhaak LR, Lebrilla CB (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340844  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340844'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340844" class="external text external">"Glycans in the immune system and The Altered Glycan Theory of Autoimmunity"</a>. <i>J Autoimmun</i>. <b>57</b> (6): 1–13. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaut.2014.12.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaut.2014.12.002'" tppabs="https://doi.org/10.1016%2Fj.jaut.2014.12.002" class="external text external">10.1016/j.jaut.2014.12.002</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340844  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340844'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340844" class="external text external">4340844</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25578468  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25578468'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25578468" class="external text external">25578468</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/rituximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/rituximab'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/rituximab" class="external text external">"Rituximab"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/hyaluronidase%20mixture%20with%20rituximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/hyaluronidase%20mixture%20with%20rituximab'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/hyaluronidase%20mixture%20with%20rituximab" class="external text external">"Hyaluronidase mixture with Rituximab"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/ppa/rituximab-and-hyaluronidase.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/ppa/rituximab-and-hyaluronidase.html'" tppabs="https://www.drugs.com/ppa/rituximab-and-hyaluronidase.html" class="external text external">"Rituximab and Hyaluronidase (Professional Patient Advice)"</a>. <i>Drugs.com</i>.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a619047.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a619047.html'" tppabs="https://medlineplus.gov/druginfo/meds/a619047.html" class="external text external">"Rituximab and Hyaluronidase Human Injection"</a>. <i>MedlinePlus</i>.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_tumors" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Monoclonal_antibodies_for_tumors" style="font-size:114%;margin:0 4em">Monoclonal antibodies for tumors</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">Tumor<br></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adecatumumab<sup>§</sup></li>
<li>Ascrinvacumab<sup>§</sup></li>
<li>Atezolizumab</li>
<li>Cixutumumab<sup>§</sup></li>
<li>Conatumumab<sup>§</sup></li>
<li>Daratumumab</li>
<li>Drozitumab<sup>§</sup></li>
<li>Duligotumab<sup>§</sup></li>
<li>Dusigitumab<sup>§</sup></li>
<li>Enfortumab vedotin<sup>†</sup></li>
<li>Enoticumab<sup>§</sup></li>
<li>Figitumumab<sup>§</sup></li>
<li>Ganitumab<sup>†</sup></li>
<li>Glembatumumab vedotin<sup>†</sup></li>
<li>Intetumumab<sup>§</sup></li>
<li>Ipilimumab</li>
<li>Iratumumab<sup>§</sup></li>
<li>Istiratumab</li>
<li>Icrucumab<sup>§</sup></li>
<li>Lexatumumab<sup>§</sup></li>
<li>Lucatumumab<sup>§</sup></li>
<li>Mapatumumab<sup>§</sup></li>
<li>Narnatumab<sup>§</sup></li>
<li>Necitumumab</li>
<li>Nesvacumab<sup>§</sup></li>
<li>Nivolumab<sup>#</sup></li>
<li>Ofatumumab</li>
<li>Olaratumab<sup>†</sup></li>
<li>Panitumumab</li>
<li>Patritumab<sup>§</sup></li>
<li>Pembrolizumab<sup>#</sup></li>
<li>Pritumumab<sup>§</sup></li>
<li>Radretumab<sup>§</sup></li>
<li>Ramucirumab</li>
<li>Rilotumumab<sup>†</sup></li>
<li>Robatumumab<sup>§</sup></li>
<li>Seribantumab<sup>§</sup></li>
<li>Tarextumab<sup>§</sup></li>
<li>Teprotumumab<sup>†</sup></li>
<li>Tovetumab<sup>§</sup></li>
<li>Vantictumab<sup>§</sup></li>
<li>Votumumab<sup>§</sup></li>
<li>Zalutumumab<sup>†</sup></li></ul>

<dl><dt><span class="nobold">"-melu-" (melanoma)</span></dt>
<dd>Flanvotumab<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Altumomab pentetate</li>
<li>Anatumomab mafenatox</li>
<li><a href="Technetium_(99mTc)_arcitumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Technetium_(99mTc)_arcitumomab" title="Technetium (99mTc) arcitumomab">Arcitumomab</a></li>
<li>Bectumomab</li>
<li>Blinatumomab</li>
<li>Detumomab</li>
<li><a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li>
<li>Lilotomab</li>
<li>Minretumomab</li>
<li>Mitumomab</li>
<li>Moxetumomab pasudotox</li>
<li>Naptumomab estafenatox</li>
<li>Nofetumomab merpentan</li>
<li>Pemtumomab<sup>†</sup></li>
<li>Pintumomab</li>
<li>Racotumomab</li>
<li><a href="Indium_(111In)_satumomab_pendetide.htm" tppabs="https://ptable.com/wiki/compounds/A/Indium_(111In)_satumomab_pendetide" title="Indium (111In) satumomab pendetide">Satumomab pendetide</a></li>
<li>Solitomab</li>
<li>Taplitumomab paptox</li>
<li>Tenatumomab</li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a></li>
<li>3F8</li></ul>

<dl><dt><span class="nobold">"-govo-" (ovarian tumor)</span></dt>
<dd>Abagovomab</dd>
<dd>Igovomab</dd>
<dd>Oregovomab</dd></dl>

<dl><dt><span class="nobold">"-pro-" (prostate tumor)</span></dt>
<dd>Capromab pendetide</dd></dl>

<dl><dt><span class="nobold">"-colo-" (colonic tumor)</span></dt>
<dd>Edrecolomab</dd>
<dd>Nacolomab tafenatox</dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Amatuximab<sup>§</sup></li>
<li>Bavituximab<sup>§</sup></li>
<li>Brentuximab vedotin</li>
<li>Carotuximab<sup>†</sup></li>
<li><a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Derlotuximab biotin<sup>§</sup></li>
<li>Dinutuximab</li>
<li>Ensituximab<sup>§</sup></li>
<li>Futuximab<sup>§</sup></li>
<li>Girentuximab<sup>†</sup></li>
<li>Indatuximab ravtansine<sup>§</sup></li>
<li>Isatuximab</li>
<li>Loncastuximab tesirine</li>
<li>Margetuximab<sup>†</sup></li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a><sup>#</sup></li>
<li>Siltuximab</li>
<li>Ublituximab<sup>†</sup></li>
<li>IMAB362</li></ul>

<p>"-mexi-" (melanoma): Ecromeximab<sup>§</sup></p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abituzumab<sup>§</sup></li>
<li><a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li>
<li>Belantamab mafodotin</li>
<li>Bevacizumab</li>
<li>Bivatuzumab mertansine<sup>§</sup></li>
<li>Brontictuzumab<sup>§</sup></li>
<li>Cantuzumab mertansine<sup>§</sup></li>
<li>Cantuzumab ravtansine<sup>§</sup></li>
<li>Cirmtuzumab</li>
<li>Citatuzumab bogatox<sup>§</sup></li>
<li>Clivatuzumab tetraxetan</li>
<li>Cofetuzumab pelidotin</li>
<li>Dacetuzumab<sup>§</sup></li>
<li>Demcizumab<sup>§</sup></li>
<li>Dalotuzumab<sup>§</sup></li>
<li>Denintuzumab mafodotin<sup>§</sup></li>
<li>Elotuzumab</li>
<li>Emactuzumab<sup>§</sup></li>
<li>Emibetuzumab<sup>§</sup></li>
<li>Enoblituzumab<sup>§</sup></li>
<li>Etaracizumab<sup>§</sup></li>
<li>Farletuzumab<sup>§</sup></li>
<li>Ficlatuzumab<sup>§</sup></li>
<li>Flotetuzumab<sup>§</sup></li>
<li>Gemtuzumab ozogamicin</li>
<li>Imgatuzumab<sup>§</sup></li>
<li>Inotuzumab ozogamicin<sup>†</sup></li>
<li>Labetuzumab<sup>§</sup></li>
<li>Lifastuzumab vedotin<sup>§</sup></li>
<li>Lintuzumab<sup>§</sup></li>
<li>Lorvotuzumab mertansine<sup>§</sup></li>
<li>Lumretuzumab<sup>§</sup></li>
<li>Matuzumab<sup>§</sup></li>
<li>Milatuzumab<sup>§</sup></li>
<li>Nimotuzumab<sup>†</sup></li>
<li>Obinutuzumab</li>
<li>Ocaratuzumab<sup>§</sup></li>
<li>Otlertuzumab<sup>§</sup></li>
<li>Onartuzumab<sup>§</sup></li>
<li>Oportuzumab monatox<sup>†</sup></li>
<li>Parsatuzumab<sup>§</sup></li>
<li>Pertuzumab</li>
<li>Pinatuzumab vedotin<sup>§</sup></li>
<li>Polatuzumab vedotin<sup>†</sup></li>
<li>Rosmantuzumab</li>
<li>Rovalpituzumab tesirine<sup>†</sup></li>
<li>Sacituzumab govitecan</li>
<li>Sibrotuzumab<sup>§</sup></li>
<li>Simtuzumab<sup>§</sup></li>
<li>Tacatuzumab tetraxetan<sup>§</sup></li>
<li>Tigatuzumab<sup>§</sup></li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a><sup>#</sup></li>
<li>Tucotuzumab celmoleukin<sup>§</sup></li>
<li>Vandortuzumab vedotin<sup>§</sup></li>
<li>Vanucizumab<sup>§</sup></li>
<li>Veltuzumab<sup>§</sup></li>
<li>Vorsetuzumab mafodotin<sup>§</sup></li>
<li>CBR96-doxorubicin immunoconjugate</li>
<li>PankoMab</li></ul>

<dl><dt><span class="nobold">"-gozu-" (ovarian tumor)</span></dt>
<dd>Sofituzumab vedotin<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Rat/mouse hybrid<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Catumaxomab</li>
<li>Ertumaxomab<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric + humanized<br></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Depatuxizumab mafodotin<sup>†</sup></li>
<li>Duvortuxizumab</li>
<li>Ontuxizumab<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>









<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-09" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Rituximab&oldid=972032471  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Rituximab&oldid=972032471'" tppabs="https://en.wikipedia.org/wiki/?title=Rituximab&oldid=972032471">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>